IPSEN (OTCMKTS:IPSEY) Given Average Recommendation of “Hold” by Analysts

Shares of IPSEN (OTCMKTS:IPSEY) have earned a consensus recommendation of “Hold” from the six analysts that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company.

A number of analysts have recently issued reports on the company. Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Zacks Research raised IPSEN to a “hold” rating in a report on Friday, May 29th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th.

IPSEN Stock Performance

IPSEN stock opened at $46.31 on Friday. The stock has a 50-day simple moving average of $45.79 and a 200 day simple moving average of $45.77. IPSEN has a 52 week low of $31.06 and a 52 week high of $51.10.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).